IMI 2 Joint Undertaking (IMI 2 JU) - (other organisations)

SMEs, Large Enterprises, Cities, Communities & NGOs, Knowledge Centers
Research, Innovation
Funding Researchers , Health , Innovation , International Cooperation , Partnerships with Industry and Member States , Social Sciences and Humanities , Society


For the IMI2 programme (2014-2020), the total budget is €3.276 billion

Description  Go to funding source website


Other organisations
Other organisations include bodies set up as part of EU programmes and public-private partnerships between the European Commission and the industry.


IMI 2 Joint Undertaking (IMI 2 JU)


Role: To advance the development of medicines by facilitating open collaboration on research

Director: Pierre Meulien

Partners: European Union (represented by the European Commission) and the European Federation of Pharmaceutical Industries and Associations (EFPIA)

Established in: 2008

Number of staff: 37

Location: Brussels (Belgium)

Website: IMI 2 Joint Undertaking (IMI 2 JU)


Developing new medicines is difficult, costly, inefficient and time-consuming. The Innovative Medicines Initiative Joint Undertaking (IMI 2 Joint Undertaking) supports collaborative research to improve the entire development process and make it more efficient, giving patients faster access to better and safer medicines.


What it does

It improves and speeds up the development of medicines by supporting open collaboration on research to address shared challenges.

It funds collaborative research projects that bring together all the parties involved in health research, including:

  • universities
  • the pharmaceutical and other industries
  • small and medium-sized businesses
  • patient organisations
  • medicine regulators.


This approach brings results in areas of disease where safe, effective treatments are lacking (e.g. dementia) and/or where the impact on public health is greatest (e.g. diabetes, antimicrobial resistance). The Innovative Medicines Initiative Joint Undertaking also runs projects on cross-cutting issues such as medicine safety and big data.



IMI 2 JU is a public-private partnership established as a 'joint undertaking' between the EU and the European Federation of Pharmaceutical Industries and Associations, EFPIA. Both are represented equally on the Governing Board, IMI 2 JU’s main decision-making body. The board is advised by committees representing the scientific community, EU governments and countries associated with Horizon 2020. Input also comes from groups set up to coordinate IMI 2 JU’s work in specific subject areas.


How it works

IMI 2 JU’s top-level goals and priority research areas are set out in the legislation establishing the initiative and in the Strategic Research Agenda. It draws on these to launch competitive calls for proposals on specific research topics. The proposals are evaluated by independent experts.

The resulting projects are supported jointly by the EU and EFPIA. EU funding goes to partners like universities, small and medium-sized businesses and patient organisations. EFPIA companies do not receive any EU funding through the IMI 2 JU, but make in-kind contributions to projects, for example by donating their researchers’ time or providing access to facilities or resources.



The Innovative Medicines Initiative (IMI) is funded jointly by the European Union (represented by the European Commission) and the European pharmaceutical industry (represented by EFPIA, the European Federation of Pharmaceutical Industries and Associations). Details of who contributes what are set out in the legislation creating IMI1 and IMI2.

For the IMI2 programme (2014-2020), the total budget is €3.276 billion, of which:

  • €1.638 billion (half the budget) comes from the Health, Demographic Change and Wellbeing Societal Challenge of Horizon 2020, the EU's framework programme for research and innovation;
  • €1.425 billion is committed to the programme by EFPIA companies;
  • up to €213 million can be committed by other life science industries or organisations that decide to contribute to IMI2 as members or Associated Partners in individual projects.


Who benefits

  • Patients can influence research into their conditions; in the longer term, they and society in general will benefit from faster access to better, safer medicines.
  • Academic researchers and small and medium-sized businesses gain access to research funding.
  • Pharmaceutical companies gain knowledge and tools to improve their research and development activities.
  • All project participants benefit from the expertise of other partners and the opportunity to translate scientific discoveries into useful tools, thereby advancing the development of medicines.


See also

Calls for proposals

Project factsheets

Press releases

Monthly newsletter

eufundingoverview.be is een officiële website van de Vlaamse overheid
Uitgegeven door Agentschap Innoveren & Ondernemen